We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.95+0.11 (+0.48%)
At close: 4:00PM EDT

22.95 0.00 (0.00%)
After hours: 4:46PM EDT

Full screen
Previous Close22.84
Open22.86
Bid22.09 x 1300
Ask23.67 x 1000
Day's Range22.64 - 23.08
52 Week Range9.35 - 25.82
Volume176,823
Avg. Volume433,250
Market Cap1.255B
Beta0.57
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.40
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of a rolling submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for lumateperone for the treatment of schizophrenia. The Company plans to complete this NDA submission in mid-2018. In 2017 the FDA granted Fast Track designation for lumateperone for the treatment of schizophrenia.

  • GlobeNewswire8 days ago

    Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida May 29-June 1, 2018. One of the Company’s presentations at ASCP focused on the effect of lumateperone on a specific domain of negative symptoms of schizophrenia known to correlate with social function.

  • GlobeNewswire9 days ago

    Intra-Cellular Therapies to Present at the Jefferies 2018 Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Jefferies 2018 Global Healthcare Conference in New York, NY. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire10 days ago

    Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced poster presentations at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida May 29-June 1, 2018. A poster presentation (W54) entitled, “Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patients with Schizophrenia” is being presented Wednesday, May 30, 2018, 11:15 am - 1:00 pm ET. This poster will be presented by Dr. Philip D. Harvey, Leonard M. Miller Professor of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine.

  • GlobeNewswire15 days ago

    New Research: Key Drivers of Growth for CSW Industrials, Cavco Industries, Intra-Cellular Therapies, Atrion, QAD, and A V Homes — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, May 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CSW ...

  • ACCESSWIRE23 days ago

    Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

    Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).

  • GlobeNewswirelast month

    Intra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV. The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced presentations on lumateperone at the 2018 American Psychiatric Association (APA) Annual Meeting in New York, May 5-9, 2018, and at the Society of Biological Psychiatry (SOBP) Annual Meeting in New York, May 10-12, 2018. A poster presentation (P5-178) entitled “Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-Label Safety Switching Study” is being presented Monday, May 7, 2018, 10:00 am - 12:00 pm ET during Poster Session 5.

  • Associated Presslast month

    Intra-Cellular: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 65 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for ...

  • GlobeNewswirelast month

    Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Research and development (R&D) expenses for the first quarter of 2018 were $30.7 million, compared to $21.5 million for the first quarter of 2017. In the first quarter of 2017, outside costs were incurred for the Phase 3 clinical trials of lumateperone in patients with bipolar depression and dementia and other lumateperone related trials.